Literature DB >> 8749673

Pneumonia due to Chlamydia pneumoniae: prevalence, clinical features, diagnosis, and treatment.

M Kauppinen1, P Saikku.   

Abstract

The association of Chlamydia pneumoniae with pneumonia was first reported in 1985. This review summarizes the data collected during the subsequent 10 years on the prevalence, clinical features, diagnosis, and treatment of this disease, which is now associated with approximately 10% of all cases of pneumonia worldwide. Primary infections are documented most often in schoolchildren and young adults, while reinfections are prominent among the elderly. C. pneumoniae pneumonia is difficult to diagnose; its onset is often insidious, with nonpurulent sputum and without leukocytosis. The microbiological diagnosis is based on the results of serological tests, polymerase chain reaction, and culture. Tetracyclines and macrolides are effective in the treatment of C. pneumoniae pneumonia, as are new quinolones.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8749673     DOI: 10.1093/clind/21.supplement_3.s244

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  20 in total

1.  Analysis of Chlamydia pneumoniae growth in cells by reverse transcription-PCR targeted to bacterial gene transcripts.

Authors:  Shusaku Haranaga; Hideaki Ikejima; Hiroyuki Yamaguchi; Herman Friedman; Yoshimasa Yamamoto
Journal:  Clin Diagn Lab Immunol       Date:  2002-03

2.  Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America.

Authors:  J G Bartlett; S F Dowell; L A Mandell; T M File; D M Musher; M J Fine
Journal:  Clin Infect Dis       Date:  2000-09-07       Impact factor: 9.079

3.  A Chlamydia-specific C-terminal region of the stress response regulator HrcA modulates its repressor activity.

Authors:  Allan L Chen; Adam C Wilson; Ming Tan
Journal:  J Bacteriol       Date:  2011-09-30       Impact factor: 3.490

Review 4.  Evolution to a chronic disease niche correlates with increased sensitivity to tryptophan availability for the obligate intracellular bacterium Chlamydia pneumoniae.

Authors:  Wilhelmina M Huston; Christopher J Barker; Anu Chacko; Peter Timms
Journal:  J Bacteriol       Date:  2014-03-28       Impact factor: 3.490

5.  Analysis of the humoral immune response to Chlamydia pneumoniae by immunoblotting and immunoprecipitation.

Authors:  A Essig; U Simnacher; M Susa; R Marre
Journal:  Clin Diagn Lab Immunol       Date:  1999-11

6.  Comparison of eleven commercial tests for Chlamydia pneumoniae-specific immunoglobulin G in asymptomatic healthy individuals.

Authors:  Corinna Hermann; Kathrin Graf; Annemarie Groh; Eberhard Straube; Thomas Hartung
Journal:  J Clin Microbiol       Date:  2002-05       Impact factor: 5.948

7.  Cytokine response of lymphocytes persistently infected with Chlamydia pneumoniae.

Authors:  Riho Takano; Hiroyuki Yamaguchi; Shigehiro Sugimoto; Shinichi Nakamura; Herman Friedman; Yoshimasa Yamamoto
Journal:  Curr Microbiol       Date:  2005-03-15       Impact factor: 2.188

8.  Chlamydophila pneumoniae PknD exhibits dual amino acid specificity and phosphorylates Cpn0712, a putative type III secretion YscD homolog.

Authors:  Dustin L Johnson; James B Mahony
Journal:  J Bacteriol       Date:  2007-08-31       Impact factor: 3.490

9.  Chlamydophila pneumoniae re-infection triggers the production of IL-17A and IL-17E, important regulators of airway inflammation.

Authors:  Tímea Mosolygó; József Korcsik; Emese Petra Balogh; Ildikó Faludi; Dezső P Virók; Valéria Endrész; Katalin Burián
Journal:  Inflamm Res       Date:  2013-02-06       Impact factor: 4.575

10.  The cell-penetrating peptide, Pep-1, has activity against intracellular chlamydial growth but not extracellular forms of Chlamydia trachomatis.

Authors:  Narae Park; Kinrin Yamanaka; Dat Tran; Pete Chandrangsu; Johnny C Akers; Jessica C de Leon; Naomi S Morrissette; Michael E Selsted; Ming Tan
Journal:  J Antimicrob Chemother       Date:  2008-10-27       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.